Eli Lilly is projected to reach $137 billion in annual sales by 2032, nearly 60% more than AbbVie, according to an Evaluate report. The company's contrarian strategy, focusing on cardiometabolic disease and Alzheimer's rather than oncology, has driven its rise from ninth to first in the Pharma 50…
While many pharmaceutical companies are scrambling to rebuild their pipelines as valuable drugs lose patent protection, Eli Lilly has opened an enormous lead over its industry peers. The company's annual sales, fueled by an expanding portfolio, could reach $137 billion per year by 2032, nearly 60% more than its closest competitor, AbbVie, according to a recent Evaluate report.
Dan Chancellor, vice president of thought leadership at Norstella, Evaluate's parent company, said the current gap between the top pharma company and the rest is unprecedented. “I can’t think of a time when there was such a distance between the No. 1 pharma company and the pack,” he said.
Lilly has relatively limited exposure to looming patent expirations, which has allowed it to climb from ninth to first place this year in Drug Discovery & Development's annual Pharma 50 rankings, just ahead of Merck & Co. in terms of revenue. The company's future growth will be fueled not only by its existing blockbuster diabetes and obesity drugs Mounjaro and Zepbound but also by a daily pill option called Foundayo, which was approved earlier this year.
According to Evaluate, sales projections also include Lilly's investigational weight-loss options, such as retatrutide, which clinical trial data suggest could beat currently approved drugs in terms of weight loss. Another contender in the pipeline, eloralintide, targets the pancreatic hormone amylin, an approach that could address some of the major tolerability issues with current weight-loss medications.
The projected value of tirzepatide, the active ingredient in Mounjaro and Zepbound, could reach $70 billion by 2032, making it the world's best-selling drug if that forecast holds. Additionally, Lilly might expect about $9.8 billion in revenue from its two investigational weight-loss drugs, retatrutide and eloralintide, by 2032, according to Evaluate.
Lilly's growth rate is six times as fast as that of some Big Pharma companies, including Merck, Novartis, and Novo Nordisk. While Novo Nordisk was the early leader in the GLP-1 space, Lilly overtook its competitor last year.
“Lilly is the only company in the top 10 pharmas that is growing above average market rates. Every other company has below average growth rates,” Chancellor said.
Chancellor attributes Lilly's success to the novel path the company has traveled in an industry that often plays follow-the-leader. Rather than investing heavily in oncology like many other companies, Lilly has moved into different therapeutic spaces, such as cardiometabolic disease and Alzheimer's disease. “It's a brave place to be a contrarian in the pharmaceutical industry,” he said.
This contrarian approach has allowed Lilly to capture significant market share in areas where competitors have been slower to enter. The company's focus on metabolic diseases and central nervous system conditions has paid off as the demand for weight-loss and diabetes treatments has surged, while Alzheimer's represents a large unmet need.
Despite its current lead, Lilly is not resting on its success. The company has been investing aggressively in its pipeline, securing agreements that included $10.8 billion in total upfront payments in the first four months of 2026. These deals involved Kelonia Therapeutics, an oncology-centered biotech; Orna Therapeutics, which specializes in autoimmune diseases; and Centessa Pharmaceuticals, which focuses on central nervous system conditions.
However, competitors could still narrow the gap. Chancellor noted that while he cannot forecast a specific merger, a deal between two companies could help bridge some of that lead. “Obviously we can't forecast a deal between two companies that we don't know that are talking. There could be a deal in the works that could help bridge some of that lead,” he said.
The pharmaceutical landscape remains dynamic, and while Lilly currently holds a commanding position, rivals are watching closely. The Evaluate report underscores that Lilly's growth is an outlier in an industry where most large pharmas are experiencing below-average growth rates. For now, the company's combination of blockbuster drugs, a strong pipeline, and a contrarian strategy has set it apart.
Peptides referenced: Tirzepatide, Retatrutide, Amylin, Eloralintide, GLP-1.
Related reading: Novel GLP-1 Agonist XANTOBI Allows Patients to Leave Current Timeline, Secret Shopper Study Examines GLP-1 Telehealth Platforms, U.S. Obesity Rate Declines While GLP-1 Drug Use Increases, Nestlé to Modify Recipes for Duller GLP-1 Palates.